Heart failure & cardiomyopathies
Mobile Integrated Health vs a Transitions of Care Coordinator for Patients Discharged After Heart Failure: The Mighty-Heart Randomized Clinical Trial
Authors' conclusion
This randomized clinical trial found that MIH conferred no additional benefit on health status or 30-day readmissions for postacute patients with heart failure compared to TOCC alone.
Study context
- Population
- Medicare- or Medicaid-enrolled adults hospitalised with HF, 11 New York City hospitals, January 2021–September 2024
- Participants
- 2,003 participants
- Comparison
- Mobile integrated health (MIH) plus TOCC vs TOCC alone
- Primary endpoint
- Coprimary: health status (KCCQ Overall Summary score) and all-cause hospital readmission
- Follow-up
- 30 days
Methodological details1:1 randomisation, 11 New York City hospitals, Data analysis September 2024 to June 2025
- 1:1 randomisation
- 11 New York City hospitals
- Data analysis September 2024 to June 2025
Primary result
As reported in the abstract
Coprimary: KCCQ Overall Summary score at 30 days; 30-day all-cause readmission
Mean difference
1.83
95% CI −0.75 to 4.40
P = 0.16
Between MIH and TOCC
mean difference 1.83 (95% CI −0.75 to 4.40); P = 0.16
- 30-day readmissions, odds ratio 0.99 (95% CI, 0.83 to 1.19)
- P = 0.95
Secondary outcomes
| Outcome | β (95% CI) |
|---|---|
| KCCQ, age-by-treatment interaction (exploratory) · 30 daysYounger participants: larger improvement with MIH · significant age-by-treatment interaction | 4.40 (1.01–7.79) |
Original publication
Mobile Integrated Health vs a Transitions of Care Coordinator for Patients Discharged After Heart Failure: The Mighty-Heart Randomized Clinical Trial. JAMA Intern Med. Published 1 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →